Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Post by Duster340on Jun 07, 2021 12:12pm
233 Views
Post# 33340422

My Two Cents

My Two Cents It is management that wants the stock to stay at these levels untill they are ready to quietly load up on insider buying, just prior to the (nr) of the start of p3. my advice is to keep an eye on any sudden jump in price or insider buying of the stock remember the game is rigged the greedy insiders will profit the most and they want the stock price to be as high as possble by the first week of october when first round of rsu's vest. i was thinking the (nr) will be in september, but now am leaning towards august followed by a string of other (nr) including the 6 week "AME' study results which i am guessing they are holding back (smart) because the stock wont react if it was to be released now. i am also expecting a possible partnering deal. but no nasdaq until possitive p3 results are announced. then in early 2022 with good p3 results either a move to nasdaq or takeout offer by bayer they will be the 1st in the know of p3 results. i am puting a $20-$30 stock price on a buyout.
<< Previous
Bullboard Posts
Next >>